ADIA · XBRL financial data
Adia Nutrition financial statements, every fiscal year
The same tables from 1 filing, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ADIA's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Revenue | 701 |
| Cost of revenue | 509 |
| Gross profit | 192 |
| Research and development | 29 |
| General and administrative | 480 |
| Total operating expenses | 558 |
| Operating income (loss) | (366) |
| Interest expense | 32 |
| Income tax expense (benefit) | 0 |
| Net income (loss) | (395) |
| Earnings per share, basic USD per share | 0.00 |
| Earnings per share, diluted USD per share | 0.00 |
| Weighted average shares, basic thousands of shares | 93,597 |
| Weighted average shares, diluted thousands of shares | 93,597 |
Balance sheet
CSVFiscal years (ADIA's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Cash and cash equivalents | 79 |
| Accounts receivable | 33 |
| Inventory | 25 |
| Total current assets | 162 |
| Property and equipment, net | 31 |
| Right-of-use asset | 108 |
| Total assets | 595 |
| Accounts payable | 2 |
| Total current liabilities | 145 |
| Lease liability, non-current | 46 |
| Total liabilities | 853 |
| Accumulated deficit | (15,973) |
| Total stockholders' equity | (258) |
| Total liabilities and equity | 595 |
| Common shares outstanding (cover page) thousands of shares | 94,405 |
Cash flows
CSVFiscal years (ADIA's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Net income (loss) | (395) |
| Stock-based compensation | 42 |
| Depreciation and amortization | 4 |
| Net cash from operating activities | (179) |
| Purchases of property and equipment | 13 |
| Net cash from investing activities | (32) |
| Proceeds from issuing common stock | 70 |
| Net cash from financing activities | 284 |
| Net change in cash | 73 |
Compare with peers
SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Adia Nutrition | 128 | 485 | (109)* | 94.4M | 1.2 quarters | 10-QJun 30, 2026 |
| Silo Pharma | 3,277 | 0* | (782)* | 1.6M | 6.7 quarters | 10-QJun 30, 2026 |
| Skinvisible | 4 | 5 | 2.2* | 5.4M | — | 10-QJun 30, 2026 |
| Xenetic Biosciences | 6,472 | 661 | (875)* | 2.3M | 7.4 quarters | 10-QJun 30, 2026 |
| LFTD Partners | 1,504 | 8,705 | (555)* | 14.8M | 2.7 quarters | 10-QJun 30, 2026 |
| Natural Alternatives International | 7,388 | not reported | (1,066)* | 22.1M | 6.9 quarters | 10-KJun 30, 2026 |
| PharmaCyte Biotech | 17,739 | 0 | (781) | 10.7M | 22.8 quarters | 10-QJul 31, 2026 |
| Vyome Holdings | 7,888 | 27 | (904)* | 7.0M | 8.7 quarters | 10-QJun 30, 2026 |
| AIM ImmunoTech | 9,900 | 26 | (4,590)* | 30.4M | 2.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.